Stockreport

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-effi [Read more]